comparemela.com

Latest Breaking News On - Runway expected - Page 1 : comparemela.com

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights

01.05.2024 - - Achieved $14.1 Million in Net Revenue from Sales of COSELA (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib .

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.